Trials / Completed
CompletedNCT00442325
Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets
ACTFAST (2): Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration: A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 mg, 20 mg, 40 mg, And 80 mg.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 595 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
European physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol. The study evaluates if selecting the starting dose based on baseline and target LDL-C cholesterol would provide better results (ie proportion of subjects resching target)
Conditions
- Coronary Arteriosclerosis
- Diabetes Mellitus, Type 2
- Cerebrovascular Accident
- Dyslipidemia
- Peripheral Vascular Disease
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atorvastatin (Lipitor) |
Timeline
- Start date
- 2003-01-01
- Completion
- 2004-02-01
- First posted
- 2007-03-01
- Last updated
- 2021-02-18
Locations
32 sites across 8 countries: Greece, Hungary, Ireland, Poland, Portugal, Russia, Slovakia, Switzerland
Source: ClinicalTrials.gov record NCT00442325. Inclusion in this directory is not an endorsement.